Niva Bupa Health Insurance profit surges 93% in Q1FY27 on margin gains
Niva Bupa Health Insurance reported a 93% YoY surge in Q1FY27 net profit to ₹137.8 crore, driven by a 23% rise in gross written premium to ₹2,306.2 crore and significant margin improvement, with the CISR improving to 100.2%. The board also approved raising up to ₹500 crore via NCDs on a private placement basis.
*this image is generated using AI for illustrative purposes only.
Niva Bupa Health Insurance Company Limited reported a net profit of ₹137.8 crore for the quarter ended June 30, 2026, marking a 93% year-on-year increase from ₹71.4 crore in Q1FY26. The insurer's gross written premium (GWP) grew 23% YoY to ₹2,306.2 crore (without 1/n basis), while retail health GWP expanded sharply by 35.5% to ₹1,764.4 crore. This strong top-line growth was underpinned by improved underwriting discipline, which saw the combined insurance service ratio (CISR) improve by 296 basis points to 100.2% from 103.2% in the prior year period. The results reflect the company's transition to Indian Accounting Standards (Ind AS) effective April 1, 2026.
The Board of Directors also approved raising funds up to ₹500 crore through the issuance of listed, rated, unsecured, subordinated, redeemable, and non-convertible debentures (NCDs) on a private placement basis. A Debt Raising Committee has been constituted to finalize the terms and conditions of the issuance. The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance Highlights
The company's financial performance for Q1FY27 showed strength across key metrics, with investment income contributing significantly to the bottom line. Total assets stood at ₹118,817 lakh, while total equity increased to ₹38,358 lakh. The solvency ratio remained robust at 2.25 times. Insurance revenue rose 29% YoY to ₹2,273.7 crore (₹22,737 lakh).
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Gross Written Premium (Without 1/n): | ₹2,306.2 crore | ₹1,874.6 crore | +23.00% |
| Retail Health GWP (Without 1/n): | ₹1,764.4 crore | ₹1,302.3 crore | +35.50% |
| Net Profit (Ind AS): | ₹137.8 crore | ₹71.4 crore | +92.90% |
| Combined Insurance Service Ratio: | 100.20% | 103.20% | -300 bps |
| Claims Ratio: | 63.00% | 66.80% | -380 bps |
The expense ratio declined slightly to 37.2% from 36.4% in the corresponding quarter last year, though the overall CISR improvement indicates better overall underwriting profitability. Investment income totaled ₹197.5 crore (₹1,975 lakh), up from ₹163.1 crore (₹1,631 lakh) in Q1FY26. The claims settlement ratio improved to 95.6% from 93.6%.
What the Numbers Show
A key analytical observation is the divergence between revenue growth and profit growth, driven by margin expansion rather than volume alone. While insurance revenue grew by 29%, net profit nearly doubled. This suggests that the improvement in the insurance service margin was the primary driver of profitability, rather than just top-line expansion. The reduction in the claims ratio by over 380 basis points points to effective risk selection or lower claim frequency/severity in the quarter. Additionally, the retail health market share increased to 11.1% from 10.0%, indicating successful penetration in the high-growth segment.
Operational and Strategic Updates
Niva Bupa's Weighted Episodal Net Promoter Score (NPS) for Q1FY27 stood at 62, an improvement of 5 points over Q1FY26, reflecting continued pursuit of service excellence. The company ranked 41st among India's Top 100 Great Places to Work 2026, improving from 67th rank last year.
Joint Statutory Auditors S.R. Batliboi & Co. LLP and Nangia & Co LLP issued an unmodified conclusion on the unaudited financial results. The company has filed an application with the Insurance Regulatory and Development Authority of India (IRDAI) for forbearance of Expenses of Management (EOM) exceeding the allowable limit for FY2024-25; approval is pending. As per IRDAI regulations, the company is not required to transfer excess EOM amounts to the profit and loss account for the current quarter, with the EOM ratio standing at 35.15% against the allowed limit of 36.24%.
Additionally, the company allotted 1,776,932 equity shares pursuant to the exercise of employee stock options during the quarter. There were no shareholder complaints received or pending during the period.
Historical Stock Returns for Niva Bupa Health Insurance Company
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.21% | +1.33% | +1.54% | +10.04% | +1.85% | +16.08% |
How will the ₹500 crore NCD issuance impact Niva Bupa's capital adequacy and future expansion plans in the retail health segment?
Can the improved CISR of 100.2% be sustained in subsequent quarters given the rising medical inflation trends in India?
What is the expected timeline for IRDAI's approval of the EOM forbearance, and how might a delay affect the company's expense management strategy?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
